Prior to joining KitoZyme, Blondel has gained broad experience in the management of innovation driven companies. He started his career in the chemical and oil and gas sectors, with assignments both in the US and in Europe. In 1999, he joined International Brachytherapy (IBt), a startup in the medical device sector focused on cancer treatment. He served as CEO, leading IBt, a Euronext stock listed company, from its R&D stage to a successful and well-diversified international group and European leader in its sector.
Today, he is also serving as a board member of Compagnie du Bois Sauvage (diversified holding company listed on Euronext), Sopartec (holding of UCL university spinoffs), Nanocyl (world leader in production of carbon nanotubes), and a number of other companies active in the technology sector.